Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
You may also be interested in...
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
Although Lilly Japan's 2022 sales declined 13% on the losses of exclusivity for two important products, the subsidiary has high hopes for three new drugs and other indication expansions. Its first-ever decentralized clinical trial involving Japanese patients, for Alzheimer's candidate donanemab, also turned out successfully.